January 2020


Do Social Values and Institutional Context Shape the Use of Economic Evaluation in Reimbursement Decisions? An Empirical Analysis

Health Years in Total: A New Health Objective Function for Cost-Effectiveness Analysis

HTA Around the World: Broadening Our Understanding of Cross-Country Differences

 

February 2020


Quebec Health-Related Quality-of-Life Population Norms Using the EQ-5D-5L: Decomposition by Sociodemographic Data and Health Problems

Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions

Why Reinvent the Wheel? Use or Modification of Existing Clinical Outcome Assessment Tools in Medical Product Development

 

March 2020


Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs

Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force

Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting

 

April 2020


Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report

Is There a Future for Value-Based Contracting?

Managed Entry Agreements: Policy Analysis From the European Perspective

Using the Choice Sequence in Time Trade-Off as Discrete Choices: Do the Two Stories Match?

 

May 2020


Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the ISPOR Personalized Precision Medicine Special Interest Group

Competing Views on the English EQ-5D-5L Valuation Set?

How Are Incremental Cost-Effectiveness, Contextual Considerations, and Other Benefits Viewed in Health Technology Assessment Recommendations in the United States?

Informing Patient-Centered Care Through Stakeholder Engagement and Highly Stratified Quantitative Benefit–Harm Assessments

 

June 2020


Defining Patient Engagement in Research: Results of a Systematic Review and Analysis: Report of the ISPOR Patient-Centered Special Interest Group

Research and Policy Impact of Trials Published by the UK National Institute of Health Research (2006-2015)

Computing the Expected Value of Sample Information Efficiently: Practical Guidance and Recommendations for Four Model-Based Methods

Acceptability and Validity of the EQ-5D in Patients Living With Dementia

An Investigation of the Stability of Patients’ Treatment Preferences Over the Course of a Clinical Trials

 

July 2020


Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions—Report of the ISPOR Stated Preference Research Special Interest Groups

Estimation of an Instrument-Defined Minimally Important Difference in EQ-5D-5L Index Scores Based on Scoring Algorithms Derived Using the EQ-VT Version 2 Valuation Protocols

EQ-5D–Derived Health State Utility Values in Hematologic Malignancies: A Catalog of 796 Utilities Based on a Systematic Review

 

August 2020


Patient-Centered Care for Women: Delphi Consensus on Evidence-Derived Recommendations

Cured Today, Ill Tomorrow: A Method for Including Future Unrelated Medical Costs in Economic Evaluation in England and Wales

ICER Value Framework 2020 Update: Recommendations on the Aggregation of Benefits and Contextual Considerations

Economic Evaluation of Interventions to Address Opioid Misuse: A Systematic Review of Methods Used in Simulation Modeling Studies

 

September 2020


Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiatives

Are We Making a Difference? A Qualitative Study of Patient Engagement at the pan-Canadian Oncology Drug Review: Perspectives of Patient Groups

Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge

A Review of Methodological Considerations for Economic Evaluations of Gene Therapies and Their Application in Literature

 

October 2020


Evaluation of the National Institute for Health and Care Excellence Diagnostics Assessment Program Decisions: Incremental Cost-Effectiveness Ratio Thresholds and Decision-Modifying Factors

Use of Real-World Evidence to Support FDA Approval of Oncology Drugs

Willingness to Pay for Health Improvements Using Stated Preferences: Prevention Versus Treatment

 

November 2020


Willingness to Accept Trade-Offs Among COVID-19 Cases, Social-Distancing Restrictions, and Economic Impact: A Nationwide US Study

Practical Guidance for Including Future Costs in Economic Evaluations in The Netherlands: Introducing and Applying PAID 3.0t

Informing Balanced Investment in Services and Health Systems: A Case Study of Priority Setting for Tuberculosis Interventions in South Africa

Head-to-Head Comparison of the Psychometric Properties of 3 Carer-Related Preference-Based Instruments

 

December 2020


Alternative Approaches to Quality-Adjusted Life-Year Estimation Within Standard Cost-Effectiveness Models: Literature Review, Feasibility Assessment, and Impact Evaluation

Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis

Patient–Provider Discussion About Cancer Treatment Costs and Out-of-Pocket Spending: Implications for Shared Decision Making in Cancer Care

Nature and Predictors of Response Changes in Modified-Delphi Panels

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×